Skip to main content
GutCited

Butyrate (Sodium/Calcium Butyrate) لـ Crohn's Disease

C

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

الخلاصة

Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.

Key Study Findings

Randomized Controlled Trial n=140 Double-blind
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …
Dose: None مقابل: placebo plus conventional therapy Outcome: clinical disease activity and fecal calprotectin التأثير: None p=0.013

المجتمع المدروس: IBD patients (60 Crohn's disease, 80 ulcerative colitis)

In Vitro
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and …
Dose: Low-dose and high-dose NaB مقابل: DSS-induced IBD mice; 5-ASA control Outcome: IBD symptom alleviation and ferroptosis inhibition التأثير: None None

المجتمع المدروس: DSS-induced IBD murine model

In Vitro
Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota.
Dose: 5 mg/mL مقابل: LPS-treated cell models Outcome: Intestinal barrier function and gut microbiota التأثير: None None

المجتمع المدروس: Caco-2 cells, RAW264.7 macrophages, fecal fermentation

Other
Association of Inflammatory Factors and Calcium Metabolism With Arthritis in Patients With Inflammatory Bowel Disease: …
Dose: None مقابل: None Outcome: Causal associations IBD → arthritis subtypes (MR) التأثير: OR=1.21 (IBD→AS); OR=1.18 (IBD→PsA) <0.001 (AS); 0.007 (PsA)

المجتمع المدروس: Mendelian randomization study of IBD and arthritis

Observational Study n=212
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.
Dose: None مقابل: Healthy controls Outcome: CD-specific microbiome signatures (AUC 0.94) التأثير: AUC 0.94 in external validation None

المجتمع المدروس: Crohn's disease and ulcerative colitis patients

In Vitro
Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot …
Dose: None مقابل: Untreated Crohn's disease microbiota Outcome: Gut microbiome modulation and inflammation التأثير: None None

المجتمع المدروس: Crohn's disease fecal microbiota in SHIME model

Key Statistics

2

الدراسات

200

المشاركون

Positive

C

التقييم

Referenced Papers

Langenbeck's archives of … 2025 3 اقتباسات
Terapevticheskii arkhiv 2019 50 اقتباسات
Current opinion in … 2019 5 اقتباسات
Current pharmaceutical design 2018 108 اقتباسات
PLoS computational biology 2018 29 اقتباسات
Gastroenterology 2017 335 اقتباسات
Best practice & … 2017 14 اقتباسات
Innate immunity 2017 13 اقتباسات
Inflammatory bowel diseases 2015 222 اقتباسات
Alimentary pharmacology & … 2005 227 اقتباسات
Alimentary pharmacology & … 2003 179 اقتباسات
Current opinion in … 2001 45 اقتباسات
Current opinion in … 2001 38 اقتباسات
Current opinion in … 2000 21 اقتباسات
Diseases of the … 1998 26 اقتباسات
The Journal of … 1994 29 اقتباسات
Digestive diseases (Basel, … 1993 29 اقتباسات

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

الجرعات الشائعة

general:
150-600 mg/day sodium or calcium butyrate
ibdsupport:
300-600 mg three times daily (900-1,800 mg/day)
butyrateenema:
100 mM butyrate enema for distal UC (clinical setting only)

الحد الأعلى: No established upper limit for oral supplements; most studies use 600-4,000 mg/day

الجرعات المدروسة في الأبحاث

الجرعة المدة التأثير ن
None -- Positive 140
Low-dose and high-dose NaB -- Positive --
5 mg/mL -- Positive --
None -- Positive --
None -- Positive 212
None -- Positive --
None -- Negative --
None -- Mixed --

أفضل وقت للتناول: With meals; enteric-coated formulations recommended to reach the colon

Safety & Side Effects

الآثار الجانبية المُبلّغ عنها

  • Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
  • Mild GI discomfort (nausea, bloating)
  • Belching with butyric acid odor
  • Enteric-coated formulations reduce taste issues

التفاعلات المعروفة

  • 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
  • No significant adverse drug interactions known

الحد الأقصى المسموح به: No established upper limit for oral supplements; most studies use 600-4,000 mg/day

استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.

Frequently Asked Questions

Does Butyrate (Sodium/Calcium Butyrate) help with Crohn's Disease?
Based on 2 studies with 200 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Butyrate (Sodium/Calcium Butyrate) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Butyrate (Sodium/Calcium Butyrate)?
Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.

Related Evidence

مكونات أخرى لـ Crohn's Disease

Butyrate (Sodium/Calcium Butyrate) لحالات أخرى

إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.